51. Identification of plasma miR-106a-5p and miR-30a-5p as potential biomarkers for mesangial proliferative glomerulonephritis
- Author
-
Quanming Zou, Hongwen Zhao, Ting Yu, Jie Lin, Huhai Zhang, Dongping Cai, Baolian Liu, Lina Wang, Qianfei Zuo, Bin Xiao, Hui Mao, and Bingbing Shen
- Subjects
Adult ,Male ,030213 general clinical medicine ,Glomerulonephritis, Membranoproliferative ,Clinical Biochemistry ,Renal function ,In situ hybridization ,030204 cardiovascular system & hematology ,Mir 30a 5p ,Real-Time Polymerase Chain Reaction ,03 medical and health sciences ,0302 clinical medicine ,Glomerulonephritis ,Membranous nephropathy ,microRNA ,medicine ,Biomarkers, Tumor ,Humans ,Circulating MicroRNA ,Receiver operating characteristic ,business.industry ,Gene Expression Profiling ,General Medicine ,Middle Aged ,medicine.disease ,MicroRNAs ,ROC Curve ,Mesangial Cells ,Cancer research ,Biomarker (medicine) ,Mesangial proliferative glomerulonephritis ,Female ,business ,Transcriptome - Abstract
Background Although stable microRNAs (miRNAs) are present in human peripheral blood and have been considered as novel biomarkers for various diseases. But there is little research about miRNAs as biomarkers of mesangial proliferative glomerulonephritis (MsPGN). This study aimed to identify whether there exist disordered circulating miRNAs that can function as biomarkers for MsPGN disease activity. Methods The candidate miRNAs were validated in 70 MsPGN patients and 70 healthy controls by quantitative real-time PCR (RT-qPCR). The specificity and sensitivity of the miRNA panel was assessed by receiver operating characteristic (ROC) curves. In addition, the candidate miRNA levels were measured in the different MsPGN progression and in the membranous nephropathy (MN) patients and the hypothetical role of the candidate miRNA on mesangial cell proliferation was analysed. Situ hybridization was performed to examine the candidate miRNA levels in the glomerulus. Results These results showed that miR-106a-5p and miR-30a-5p were highly expressed in MsPGN patients compared with healthy controls and could discriminate MsPGN from healthy controls with an area under the ROC curve (AUC) of 0.93. In addition, the two miRNAs were not only higher in moderate and severe MsPGN patients, but could distinguish MsPGN from MN. We also observed a decreased expression in MsPGN regression group after treatment. Plasma miR-106a-5p level was positively correlated with estimated glomerular filtration rate (eGFR). Furthermore, the two miRNAs were highly expressed in MsPGN glomerulus and their overexpression could prompt mesangial cell proliferation. Conclusion Plasma miR-30a-5p and miR-106a-5p can serve as novel and potential diagnostic biomarkers for MsPGN.
- Published
- 2020